Seoul, South Korea Aug 19, 2021 - GC Labs and KNCV Tuberculosis Foundation (KNCV) will present their newly formed alliance during an online event on the 18th of August. The two organizations will collaborate on a project for 'Strengthening tuberculosis (TB) treatment Safety Monitoring' in Kyrgyzstan and Vietnam. The project is aimed at quality control of non-bacteriological tests, for example, blood tests. These tests are crucial to monitor the wellbeing of patients starting on the novel and existing tuberculosis treatments. The early detection of any drug adverse effects and intolerance is essential to prevent undesirable consequences to the patient's health and guides doctors in their decision-making. Improved quality of the safety monitoring system, which healthcare professionals trust, leads to better treatment outcomes and patient safety through the long course of TB treatment (from six months to two years).
Eunhee Lee, President of GC Labs, will be present at the online event, as well as Dr. Mustapha Gidado, KNCV's Executive Director, and Dr. Agnes Gebhard, KNCV's Technical Director. With the help of the alliance between GC Labs and KNCV, the opportunity arises to improve the TB drug safety monitoring system in Kyrgyzstan and Vietnam. This approach will subsequently be discussed with global-level stakeholders for application and expansion in other countries as part of a standard TB care package.
Historically, the non-bacteriological laboratory tests - such as full blood count and a variety of blood chemistry tests for side effects monitoring in TB patients - have often lacked focus on quality control and standardization. When the quality of these tests fluctuates, the patient's treatment safety can be compromised. As a result, the patient's health can be negatively affected, and the TB treatment is interrupted with undesirable outcomes.
With the generous support of GC Labs, KNCV will focus on this problem from the individual patient's management level up to the global level. A significant investment by GC labs has been granted to KNCV, giving GC Labs a timely opportunity to step up its corporate social responsibility mandate. GC Labs has earned its competitive advantage by its expertise in the clinical diagnostics of patients. By partnering with KNCV, which has 118 years of experience in anti-tuberculosis activities, GC Labs contributes to KNCV's goal; a world free of TB.
To commemorate the new partnership, a ceremony is scheduled to take place on August 18th. The partnering illustrates how countries like South Korea and international non-profit organizations such as KNCV can form alliances to defeat a common enemy and improve human health conditions in low and middle-income settings. Mustapha Gidado, the Executive Director of KNCV, agrees, adding, "KNCV is honored to take part in this project with GC Labs. With the knowledge that GC Labs and KNCV have about TB control, we strongly believe that this project will greatly contribute towards relieving the suffering from TB worldwide." In a commemorative speech, Dr. Lee Eun-hee, Chairman of the GC Laboratory, said "Our clinical laboratory has had a distinctive legacy in the clinical diagnostics field across Asia and serves as the very first medical institution in Korea built specializing in diagnostic testing.
▼ Related News
[FOX40]
https://www.wicz.com/story/44561728/new-partnership-between-gc-labs-and-kncv-tuberculosis-foundation-to-strengthen-tuberculosis-treatment-safety-monitoring
[NBC]
https://www.wrde.com/story/44561728/new-partnership-between-gc-labs-and-kncv-tuberculosis-foundation-to-strengthen-tuberculosis-treatment-safety-monitoring
[Malaysia Corner]
https://malaysiacorner.com/news/new-partnership-between-gc-labs-and-kncv-tuberculosis-foundation-to-strengthen-tuberculosis-treatment-safety-monitoring/0325902